Actively Recruiting
The Pericapsular Nerve Block in Total Hip Arthroplasty A Randomized, Controlled Trial Comparing Pain Management Approaches
Led by LifeBridge Health · Updated on 2025-01-22
78
Participants Needed
1
Research Sites
259 weeks
Total Duration
On this page
Sponsors
L
LifeBridge Health
Lead Sponsor
R
Rubin Institute for Advanced Orthopedics
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the effectiveness of the pericapsular nerve block compared to the fascia iliaca nerve block for managing pain after total hip arthroplasty (THA). This Phase 4 randomized controlled trial focuses on adults with hip osteoarthritis or hip arthropathy undergoing primary total hip replacement using the anterior (Smith-Peterson) approach. Effective pain control is important for recovery, mobility, and reducing complications such as blood clots after surgery. Participants will receive one of two nerve block treatments as part of their standard care: the pericapsular nerve block or the fascia iliaca nerve block, both administered according to standard institutional practice. These nerve blocks are given around the time of surgery to help control pain. The study includes pre-operative, operative, and follow-up visits at 2 weeks and 4 to 6 weeks after surgery. During the study, pain levels will be measured every 4 hours up to 48 hours after surgery using the Visual Analog Pain Scale (VAS), and opioid use will be tracked for one month post-surgery. Participants will be monitored closely for pain control and any safety concerns. The total participation time includes surgery and follow-up visits over approximately 4 to 6 weeks.
CONDITIONS
Official Title
The Pericapsular Nerve Block in Total Hip Arthroplasty
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed and dated informed consent form
- Willingness to comply with all study procedures and availability for the duration of the study
- Planned primary total hip arthroplasty with anterior (Smith-Peterson) approach
- ASA score of 1 to 3
- Indicated for one of the two nerve block groups
- Opioid naive at screening as defined by the FDA (not taking opioids at specified doses for one week or longer)
You will not qualify if you...
- Current or previous diagnosis of chronic pain
- Opioid tolerant at time of screening (using opioids at or above specified doses for one week or longer)
- Diagnosis of ankylosing spondylitis
- Allergy to any medications used in the nerve block groups
- Conversion to general anesthesia during surgery
- Treatment with another investigational drug or intervention for pain
- Any physical or psychological condition or exam finding that would prevent participation according to the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sinai Hospital of Baltimore
Baltimore, Maryland, United States, 21215
Actively Recruiting
Research Team
M
Martin Gesheff
N
Nirav Patel
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here